

C4 Imaging Announces the Introduction of Nova Z Fiducial Markers

Houston, Texas, (Oct 31, 2025) – C4 Imaging LLC is pleased to announce the introduction of its Nova Z Fiducial Marker, a non-metallic marker designed to complement its current range of positive-signal MRI markers.

Nova Z is ideal for CT and x-ray imaging, where its non-metallic core delivers exceptional visibility with minimal impact on treatment delivery. It's particularly well suited to proton beam therapy, a modality that is increasingly utilized in the US, and one that could benefit from Nova Z's non-metallic nature.

Image guidance utilizing fiducial markers is an important option to reduce margins of uncertainty while planning radiation or proton therapy treatment. The help ensure therapy is focused on the cancer, rather than on surrounding healthy anatomy, optimizing cure rates, and minimizing the risk of side effects. Most fiducial markers contain metal, which can cause imprecise voids, or artifacts, on MR images. Nova Z Fiducial Markers are comprised of non-metallic materials that minimize artifact when viewed with MRI.

Radiation Oncologists and their teams often combine MR and CT images, referred to as co-registration or image fusion, to precisely plan where therapy will be targeted. With Nova Z they are able to co-register MR and CT images without the concern of artifacts, and then utilize Nova Z's CT or x-ray imaging properties to precisely align radiotherapy or proton delivery throughout the course of each patient's treatment.

Andrew Bright, President of C4 Imaging, commented, "We're excited to introduce Nova Z, our latest non-metallic fiducial marker." Mr. Bright added, "It was developed as a result of feedback back from leaders in the field of proton and radiation therapy and illustrates C4 Imaging's commitment to being guided by excellence and true clinical needs."

About C4 IMAGING

C4 imaging creates breakthrough non-metallic markers designed to optimize cancer treatment by improving tumor localization, resulting in precise delivery of therapy and enhanced patient outcomes. To learn more, please visit www.c4imaging.com.

For further information:
Andrew Bright
abright@c4imaging.com